Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indivior ( (INDV) ) just unveiled an announcement.
On August 20, 2025, Indivior PLC updated its employment agreements with CFO Ryan Preblick to align with current U.S. executive agreements, without altering his compensation or responsibilities. The new agreements include an annual base salary of $558,819, a cash bonus opportunity, and potential long-term incentive awards, reflecting the company’s commitment to maintaining competitive executive compensation structures.
The most recent analyst rating on (INDV) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Outperform.
Indivior’s strong technical performance and improving financial trajectory are tempered by valuation concerns and recent revenue challenges. The company’s strategic initiatives and market position offer potential for recovery, but investors should be cautious of overbought signals and balance sheet weaknesses.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, focusing on the development and distribution of addiction treatment medications. The company is known for its products aimed at treating opioid use disorder and has a significant presence in the U.S. market.
Average Trading Volume: 2,752,808
Technical Sentiment Signal: Buy
Current Market Cap: $2.93B
Find detailed analytics on INDV stock on TipRanks’ Stock Analysis page.